Premium
Recursion Pharmaceuticals Inc (RXRX)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-05 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 144,80k | Derivative Exercise and Sale | 3,62 | 300,44k | - |
| 2026-06-05 | Dr. Najat KhanCEO, President & Director | -23,59k | 84,46k | Automatic Disposition | 3,58 | 108,54k | -17,85% |
| 2026-06-02 | Dr. Blake C. BorgesonIndependent Director | -30,00k | 110,40k | Automatic Disposition | 3,68 | 6,15M | -0,49% |
| 2026-06-03 | Dr. Namandje N. BumpusIndependent Director | -4,39k | 15,53k | Automatic Disposition | 3,54 | 43,17k | -9,22% |
| 2026-05-22 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 123,20k | Derivative Exercise and Sale | 3,08 | 300,44k | - |
| 2026-05-15 | Mr. Ben R. TaylorCFO & President of Recursion UK | -25,02k | 76,05k | Sale to Issuer | 3,04 | 285,58k | -8,05% |
| 2026-05-15 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -22,82k | 69,38k | Sale to Issuer | 3,04 | 300,44k | -7,06% |
| 2026-05-15 | Dr. David HallettChief Scientific Officer | -26,66k | 81,04k | Sale to Issuer | 3,04 | 406,65k | -6,15% |
| 2026-05-15 | Dr. Najat KhanCEO, President & Director | -62,70k | 190,61k | Sale to Issuer | 3,04 | 132,13k | -32,18% |
| 2026-05-07 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -60,00k | 134,80k | Derivative Exercise and Sale | 3,37 | 244,17k | - |
| 2026-05-05 | Dr. Blake C. BorgesonIndependent Director | -30,00k | 105,60k | Automatic Disposition | 3,52 | 6,18M | -0,48% |
| 2026-04-22 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 144,40k | Derivative Exercise and Sale | 3,61 | 244,17k | - |
| 2026-04-06 | Mr. Ben R. TaylorCFO & President of Recursion UK | -48,03k | 149,37k | Sale to Issuer | 3,11 | 257,37k | -15,73% |
| 2026-04-07 | Dr. Blake C. BorgesonIndependent Director | -30,00k | 93,00k | Automatic Disposition | 3,10 | 6,21M | -0,48% |
| 2026-04-07 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 124,00k | Derivative Exercise and Sale | 3,10 | 244,17k | - |
| 2026-03-23 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 130,00k | Derivative Exercise and Sale | 3,25 | 244,17k | - |
| 2026-03-17 | Mr. Ben R. TaylorCFO & President of Recursion UK | -7,96k | 26,97k | Automatic Disposition | 3,39 | 203,21k | -3,77% |
| 2026-03-16 | Mr. Ben R. TaylorCFO & President of Recursion UK | -7,08k | 24,20k | Sale to Issuer | 3,42 | 203,21k | -3,36% |
| 2026-03-09 | Dr. Najat KhanCEO, President & Director | -28,30k | 94,66k | Automatic Disposition | 3,35 | 40,73k | -40,99% |
| 2026-03-09 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -20,00k | 0,00 | Derivative Exercise and Sale | - | 244,17k | - |
| 2026-03-03 | Dr. Blake C. BorgesonIndependent Director | -170,00k | 588,20k | Vente | 3,46 | 6,24M | -2,65% |
| 2026-02-17 | Dr. David HallettChief Scientific Officer | -11,91k | 41,56k | Sale to Issuer | 3,49 | 382,79k | -3,02% |
| 2026-02-18 | Mr. Ben R. TaylorCFO & President of Recursion UK | -13,43k | 41,35k | Automatic Disposition | 3,08 | 203,23k | -6,20% |
| 2026-02-17 | Mr. Ben R. TaylorCFO & President of Recursion UK | -11,91k | 41,56k | Sale to Issuer | 3,49 | 203,23k | -5,54% |
| 2026-02-19 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 138,40k | Derivative Exercise and Sale | 3,46 | 244,17k | - |
| 2026-02-17 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -27,27k | 95,15k | Sale to Issuer | 3,49 | 244,17k | -10,04% |
| 2026-02-17 | Dr. Najat KhanCEO, President & Director | -14,28k | 49,84k | Sale to Issuer | 3,49 | 69,03k | -17,14% |
| 2026-02-06 | Dr. David HallettChief Scientific Officer | -11,40k | 45,37k | Sale to Issuer | 3,98 | 300,78k | -3,65% |
| 2026-02-06 | Dr. Najat KhanCEO, President & Director | -10,36k | 41,25k | Sale to Issuer | 3,98 | 33,81k | -23,46% |
| 2026-02-06 | Mr. Ben R. TaylorCFO & President of Recursion UK | -11,40k | 45,37k | Sale to Issuer | 3,98 | 203,23k | -5,31% |
| 2026-02-03 | Dr. Blake C. BorgesonIndependent Director | -220,00k | 924,00k | Automatic Disposition | 4,20 | 6,41M | -3,32% |
| 2026-02-04 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 164,80k | Derivative Exercise and Sale | 4,12 | 179,33k | - |
| 2026-02-06 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -10,36k | 36,90k | Sale to Issuer | 3,56 | 179,33k | -5,46% |
| 2026-01-20 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 178,80k | Derivative Exercise and Sale | 4,47 | 159,35k | - |
| 2026-01-06 | Dr. Blake C. BorgesonIndependent Director | -220,00k | 959,20k | Automatic Disposition | 4,36 | 6,63M | -3,21% |
| 2026-01-05 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -60,00k | 170,00k | Derivative Exercise and Sale | 4,25 | 159,35k | - |
| 2025-12-29 | Mr. Ben R. TaylorCFO & President of Recursion UK | -21,38k | 89,38k | Automatic Disposition | 4,18 | 190,38k | -10,10% |
| 2025-12-22 | Dr. Najat KhanCEO, President & Director | -124,40k | 548,59k | Automatic Disposition | 4,41 | 13,83k | -90,00% |
| 2025-12-18 | Mubadala Investment Company PJSCSociété | -12,99M | 56,59M | Vente | 4,24 - 4,58 | 0,00 | -100,00% |
| 2025-12-19 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 180,00k | Derivative Exercise and Sale | 4,50 | 159,35k | - |
| 2025-12-15 | Mr. Ben R. TaylorCFO & President of Recursion UK | -7,06k | 30,56k | Sale to Issuer | 4,33 | 211,76k | -3,23% |
| 2025-12-04 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -60,00k | 185,20k | Derivative Exercise and Sale | 4,63 | 159,35k | - |
| 2025-12-02 | Dr. Blake C. BorgesonIndependent Director | -220,00k | 961,40k | Automatic Disposition | 4,37 | 6,85M | -3,11% |
| 2025-11-25 | Mr. Ben R. TaylorCFO & President of Recursion UK | -2,27k | 9,15k | Sale to Issuer | 4,03 | 203,81k | -1,10% |
| 2025-11-17 | Mr. Ben R. TaylorCFO & President of Recursion UK | -11,91k | 49,30k | Sale to Issuer | 4,14 | 201,25k | -5,59% |
| 2025-11-17 | Dr. Najat KhanCEO, President & Director | -17,58k | 72,80k | Sale to Issuer | 4,14 | 138,23k | -11,29% |
| 2025-11-19 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,00k | 166,40k | Derivative Exercise and Sale | 4,16 | 159,35k | - |
| 2025-11-17 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,39k | 167,21k | Sale to Issuer | 4,14 | 159,35k | -20,22% |
| 2025-11-04 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -60,00k | 208,40k | Derivative Exercise and Sale | 5,21 | 107,63k | - |
| 2025-10-23 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -100,00k | 570,00k | Derivative Exercise and Sale | 5,70 | 107,63k | - |
| 2025-10-10 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -120,00k | 604,00k | Derivative Exercise and Sale | 6,04 | 100,66k | - |
| 2025-09-25 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -100,00k | 476,00k | Derivative Exercise and Sale | 4,76 | 107,63k | - |
| 2025-09-15 | Mr. Ben R. TaylorCFO & President of Recursion UK | -7,06k | 34,09k | Sale to Issuer | 4,83 | 187,82k | -3,62% |
| 2025-09-10 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -120,00k | 471,00k | Derivative Exercise and Sale | 4,71 | 107,63k | - |
| 2025-08-26 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -100,00k | 484,00k | Derivative Exercise and Sale | 4,84 | 107,63k | - |
| 2025-08-18 | Dr. Najat KhanCEO, President & Director | -36,60k | 202,17k | Vente | 5,52 | 111,62k | -24,69% |
| 2025-08-15 | Dr. Najat KhanCEO, President & Director | -3,79k | 21,37k | Sale to Issuer | 5,64 | 111,62k | -3,28% |
| 2025-08-15 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -40,39k | 227,80k | Sale to Issuer | 5,64 | 107,63k | -27,29% |
| 2025-08-15 | Mr. Ben R. TaylorCFO & President of Recursion UK | -11,91k | 67,16k | Sale to Issuer | 5,64 | 179,86k | -6,21% |
| 2025-08-11 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -541,54k | 2,86M | Derivative Exercise and Sale | 5,28 | 55,91k | - |
| 2025-08-11 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -76,63k | 404,63k | Automatic Disposition | 5,28 | 55,91k | -57,82% |
| 2025-08-11 | Dr. Christopher C. GibsonCo-Founder, Chairman & Interim Executive Advisor | -10,00k | 0,00 | Other Disposition | - | 55,91k | -15,17% |
| 2025-06-16 | Mr. Ben R. TaylorCFO & President of Recursion UK | -7,06k | 34,72k | Sale to Issuer | 4,92 | 166,44k | -4,07% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
